Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.
Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.
Genentech, part of the Roche Group, reported positive Phase Ib results for its dual GLP-1/GIP receptor agonist, CT-388, in treating obesity.
Over 24 weeks, a weekly subcutaneous injection of CT-388 led to a significant placebo-adjusted weight loss of 18.8% (p < 0.001). Important results included 100% of treated participants achieving over 5% weight loss, 70% over 15%, and 45% over 20%. Additionally, pre-diabetic participants normalized their glycemia levels.
No new safety signals were detected. Adverse events were consistent with the incretin drug class. Further trials involving obese patients with type 2 diabetes are expected to report results in the second half of 2024.
Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in treating obesity and type 2 diabetes. Over 24 weeks, CT-388 achieved a significant placebo-adjusted weight loss of 18.8% (p < 0.001). At week 24, 100% of participants treated with CT-388 achieved >5% weight loss, 70% achieved >15%, and 45% achieved >20%. The treatment normalized glycemia in all pre-diabetic patients, showing strong glucose homeostasis impact. No new safety signals were detected, and the treatment was well-tolerated.
Looking forward, Roche plans to evaluate CT-388 in obese patients with type 2 diabetes over a 12-week treatment duration, with data expected in the second half of 2024.
Roche announced the FDA approval of its HPV self-collection solution, one of the first such options in the U.S. This tool improves access to HPV testing by allowing women to privately collect their own samples, which are then analyzed in a lab. The solution addresses a significant gap, as over half of U.S. cervical cancer patients are underscreened. Over 13,000 U.S. women are diagnosed with cervical cancer annually, and approximately 4,000 die from it. HPV self-collection could enable early detection and treatment, supporting the WHO's goal to eliminate cervical cancer by 2030. Roche collaborated with the National Cancer Institute for this initiative.
FAQ
What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?
What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?
What is Roche Holdings Ltd. S/ADR (RHHBY) known for?
What is the significance of Columvi® (glofitamab) in Roche's portfolio?
How does Roche contribute to personalized healthcare?
What recent innovation has Roche introduced in digital pathology?